MLV Reiterates Buy Rating On Vivus

According to MLV, Vivus VVUS Buy rating is reiterated. MLV said that it reiterates its BUY rating and $16 price target. “As a reminder, VVUS plans to conduct a retrospective fetal outcomes study using existing US electronic healthcare databases. The FORTRESS study will analyze the relative risk of major congenital malformations and oral cleft in offspring of women exposed to topiramate during pregnancy.” Vivus closed yesterday at $8.39.